MCMCB Pro
G9697

G9697Documentation of patient reason(s) for not prescribing a long-acting inhaled bronchodilator

HCPCSTerminatedBETOS Z2

G9697 is a HCPCS Level II code for documentation of patient reason(s) for not prescribing a long-acting inhaled bronchodilator. It belongs to the Procedures and Professional Services (Temporary) section. It was terminated on December 31, 2023 and is not valid on new claims.

This code has been terminated

CMS terminated G9697 on December 31, 2023. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.

The CMS record for G9697

Long descriptor
Documentation of patient reason(s) for not prescribing a long-acting inhaled bronchodilator

The official wording. This is what the code means.

Short descriptor
Pt rsn no presc bronchdil

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2017

When CMS introduced the code.

Terminated
December 31, 2023

When CMS retired it.

BETOS
Z2

Berenson-Eggers Type of Service — CMS's own analytic grouping.

Pricing indicator
00 — Not priced by Part B

Service not separately priced by Part B — not covered, bundled into another service, or used by Part A only.

Codes adjacent to G9697

HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If G9697 is not quite right, the correct code is very often within a few positions of it.

  • G9689Patient admitted for performance of elective carotid intervention
  • G9690Patient receiving hospice services any time during the measurement period
  • G9691Patient had hospice services any time during the measurement period
  • G9692Hospice services received by patient any time during the measurement period
  • G9693Patient use of hospice services any time during the measurement period
  • G9694Hospice services utilized by patient any time during the measurement period
  • G9695Long-acting inhaled bronchodilator prescribed
  • G9696Documentation of medical reason(s) for not prescribing a long-acting inhaled bronchodilator (e.g., patient intolerance or history of side effects)
  • G9698Documentation of system reason(s) for not prescribing a long-acting inhaled bronchodilator (e.g., cost of treatment or lack of insurance)
  • G9699Long-acting inhaled bronchodilator not prescribed, reason not otherwise specified
  • G9700Patients who use hospice services any time during the measurement period
  • G9701Children who are taking antibiotics in the 30 days prior to the date of the encounter during which the diagnosis was establishedterminated
  • G9702Patients who use hospice services any time during the measurement period
  • G9703Episodes where the patient is taking antibiotics (table 1) in the 30 days prior to the episode date
  • G9704Ajcc breast cancer stage i: t1 mic or t1a documented
  • G9705Ajcc breast cancer stage i: t1b (tumor > 0.5 cm but <= 1 cm in greatest dimension) documented

Questions about G9697

What is HCPCS code G9697?

G9697 is a HCPCS Level II code for documentation of patient reason(s) for not prescribing a long-acting inhaled bronchodilator. It sits in the Procedures and Professional Services (Temporary) section.

Does Medicare cover G9697?

The CMS HCPCS file marks G9697 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

Is G9697 still valid?

No. G9697 was terminated on December 31, 2023 and should not be used on new claims.

HCPCS Level II2026Q3-Jul· effective July 1, 2026